79
Professor Aigbirhio said: “In particular, we believed the network approach would bring together a larger critical mass of the range of skills needed for this type of interdisciplinary research, enhancing the sharing of ideas, technologies and best practice and establishing standard procedures across centres.
“Our overarching aim is to create a world- leading environment for applying advanced imaging to support experimental medicine and clinical trials in dementia research. Our objectives include sharing expertise and resources to enable more rapid uptake and
Professor Franklin Aigbirhio - credit Alex Tyler
application of technical advances - for example, novel radiopharmaceuticals or improved image analysis algorithms - as well as the establishment of common operating procedures and analyses for measuring outcomes, which will create an environment for rapid implementation of the highest-quality experimental medicine.
“We also aim to be a single point of access for a national imaging platform that will foster joint academic and industry dementia research towards the development of novel drugs.”
Imaging brings unique insights to the fi eld of dementia research that cannot be achieved through other means. Those insights include the ability to visualise and quantify directly in patients the biochemical and structural changes in the brain that are associated with dementia - for example, detecting the presence of toxic proteins in the brain before any symptoms occur.
And while combined PET-MR scanning for dementia research is still in its infancy as a technique, imaging technology more broadly is already achieving good results in the fi eld. Professor Aigbirhio added: “We are gaining major insights into assessing the biodistribution and impact of the key toxic proteins associated with dementia: beta- amyloid and tau. Understanding how these proteins develop and vary in different parts of the brain will help us towards improved and earlier diagnosis of the different forms of dementia, as well as understanding their disease mechanisms.
”Brain imaging technology will also give us greater insights into other components of the dementia disorders, including the increase in infl ammation and the effect on synapses. All of these are potential targets for developing vital new drugs for the treatment of dementia.”
PET MR Team - credit University of Manchester
For more information on Dementias Platform UK, including the imaging network and PET-MR scanners, visit
www.dementiasplatform.uk
Read, Share and Comment on this Article, visit:
www.labmate-online.com/article Premium AFM for Medium-sized Samples Launched
Tosca 200 is the latest addition to the Tosca series from Anton Paar, which now consists of Tosca 400, a large-sample, premium AFM, and Tosca 200, an AFM for medium-sized samples and budget-sensitive research. Both devices feature the same high level of automation, increasing the effi ciency and signifi cantly simplifying the handling of AFM measurements.
Following the introduction of Tosca 400 in 2017 as the fi rst AFM that combined premium technology with time-effi cient operation for large samples, Anton Paar now launches Tosca 200, an AFM for medium-sized samples and budget-sensitive research but providing the same quality and fl exibility.
The features that make the difference are: the Probemaster is a unique tool specifi cally developed for cantilever handling that saves time and guaran- tees the fast, safe, and correct placement of the cantilever; Tosca carries out laser alignment automatically with just two clicks in the control software; navigation on an overview map only by mouse-click which facilitates the localisation of the right measuring area, especially when working with more than one sample; the integrated side-view camera enables live tracking of the cantilever position with respect to the surface on the main screen, so the coarse approach of the probe is fast and safe and auto-engagement is then performed within seconds; the magnetic sample carrier lock for fast sample mounting means that multiple samples can be placed on the sample carrier outside of the instrument and the lock guarantees a stable position of the samples; the workfl ow-oriented Tosca Control software guides the user thorough every step of the measurement so that the fi nal results are obtained faster and the user can focus on the interpretation and further research.
With their focus on performance and measurement effi ciency, both instruments in the Tosca series are the perfect nanotechnology tools for scientists as well as industrial users. More information online:
ilmt.co/PL/WpeB
50130pr@reply-direct.com
Novel FTIR Imaging Microscope Announced
Bruker launches the novel, stand-alone FTIR imaging microscope LUMOS II on 28 October 2019, offering ultrafast FTIR imaging using focal-plane array (FPA) detectors. It is built to identify particles, determine coatings and contaminations, and to reveal polymeric compositions. It’s intended for QC and failure analysis in pharma, polymers, chemical and electronics, and forensics applications.
The LUMOS II records FTIR data in transmission, refl ection and attenuated total refl ection (ATR). By default, it is equipped with an actively cooled MCT detector to eliminate the need for liquid nitrogen. The LUMOS II accommodates up to three different detectors.
The LUMOS II microscope combines best imaging and spectral performance with user convenience. The motorised ATR crystal is integrated into the objective, allowing full automation in all modes. The intuitive interface provides all users with an easy way to achieve rapid results.
The LUMOS II fulfi ls the requirements of Good Laboratory Practice (GLP). Validation options are available for compliance with cGMP/GMP, US, ChP, JP and
Ph.Eur., and 21 CFR Part11. Most options can be upgraded at the customer’s site. Systems confi gured for routine use can be upgraded into a high-speed imaging micro- scope. Its sealed ZnSe optics make the LUMOS II inert to moisture.
More information online:
ilmt.co/PL/o00j 50828pr@reply-direct.com
WWW.LABMATE-ONLINE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
